Vabametkib plus lazertinib shows promising antitumor activity in advanced NSCLC with MET amplification resistant to 3rd-gen EGFR-TKIs

Lazcluze (lazertinib) - J&J

vabametkib (ABN401) - Abion

https://www.abstractsonline.com/pp8/#!/20273/presentation/7740

Nirmal Rajasekaran; Yeongmun Kim; Dawoon Jeong; Heesoo Ahn; Jeesun Kim; Yanghee Kim; Sangsuk Lee; Sunhye Im; Young Kee Shin; Jun Young Choi; Na Young Kim

Mar 26, 2025